NCT02486718 · OUTCOME

Overall Survival (OS) in the ITT Population

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] · Source last updated 2026-07-29

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Baseline up to death from any cause (up to approximately 126 months)

What was measured

OS was defined as the time from randomization to death from any cause.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2028-08
denom Units Selected: Participants
description: OS was defined as the time from randomization to death from any cause.
reporting Status: NOT_POSTED
time Frame: Baseline up to death from any cause (up to approximately 126 months)
title: Overall Survival (OS) in the ITT Population
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice